Both small molecules (SR13800 and AZD3965) that the target MCT1 showed anti-tumor effects on breast tumor growth in pre-clinical models [18,19,28], and AZD3965 is now being tested in clinical trials. This evidence concerns the gene SLC16A1 and neoplasm.